Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) shares dropped 9.4% during mid-day trading on Monday. The stock traded as low as $1.6625 and last traded at $1.6950. 1,198,438 shares changed hands during trading, a decline of 19% from the average session volume of 1,476,877 shares. The stock had previously closed at $1.87.
Tharimmune Price Performance
The company has a market cap of $65.27 million, a price-to-earnings ratio of -0.43 and a beta of 1.43. The stock has a 50 day simple moving average of $2.17 and a two-hundred day simple moving average of $2.62.
Tharimmune Company Profile
Tharimmune, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development activities center on treatments intended to address conditions with significant unmet medical needs.
Tharimmune’s lead development program, TH104, is an intranasal film formulation of aprepitant, a neurokinin-1 receptor antagonist. The program is being developed for chronic pruritus, including itching associated with cholestatic liver disease and other conditions.
Further Reading
- Five stocks we like better than Tharimmune
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
